Rapid and efficient generation of multigene-knockout THP-1 cells using a simple CRISPR-Cas9 protocol Authors: Chihiro Ito, Yuki Kinomura, Kensho Kawagoe, Shinobu Fujii, Toshihiro Fujii, Rikiro Fukunaga Published: 2026 ABSTRACT THP-1, a widely used human monocytic leukemia cell line, has been described as one of the hard-to-transfect suspension cell lines. Here, we present a rapid and efficient method for generating multiplex gene knockout cells from THP-1 using a simple co-transfection strategy based on the CRISPR-Cas9 system. In this method, THP-1 cells were transfected with a mixture of pX330-based sgRNA plasmids and a small amount of puromycin-resistance plasmid by electroporation, followed by transient selection with high-dose puromycin. This simple method resulted in efficient simultaneous knockout of multiple genes. For genes important for survival and/or cell proliferation, gene-knockout clones may be isolated by the limiting dilution method immediately after puromycin selection.•A simple co-transfection strategy to knock out multiple genes simultaneously in the human monocytic leukemia cell line, THP-1.•Transient selection with high-dose puromycin appeared to be effective for efficient knockout.•In general, knockout efficiency is satisfactory, and polyclonal knockout cells can be used without a cloning step unless the target gene plays a critical role in cell survival or proliferation. Specifications tableSubject areaBiochemistry, Genetics and Molecular BiologyMore specific subject areaCRISPR-Cas9-mediated gene knockoutName of your methodRapid and efficient multigene knockout in THP-1 cellsName and reference of original methodMultiplex genome engineering using CRISPR/Cas systems. Science, 339, (2013), 819–823, https://doi.org/10.1126/science.1231143Resource availabilitypX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene ID=42,230),pUREF-EX plasmid (Addgene ID=199,331) Subject areaBiochemistry, Genetics and Molecular BiologyMore specific subject areaCRISPR-Cas9-mediated gene knockoutName of your methodRapid and efficient multigene knockout in THP-1 cellsName and reference of original methodMultiplex genome engineering using CRISPR/Cas systems. Science, 339, (2013), 819–823, https://doi.org/10.1126/science.1231143Resource availabilitypX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene ID=42,230),pUREF-EX plasmid (Addgene ID=199,331) Background The CRISPR-Cas technology is a versatile tool for investigating the molecular functions of various genes in both living organisms and cultured cell lines [1]. The CRISPR-Cas-mediated genome editing utilizes double-strand break (DSB)-triggered repair pathways, such as homologous recombination (HR) and non-homologous end joining (NHEJ), with the latter prone to introducing insertions or deletions, leading to functional knockout of target genes. Generating multigene-knockout cells from cultured cell lines is useful for dissecting isotype-specific or redundant functions of individual members in a multigene family or of individual components of multiprotein complexes, and various strategies for multiplex gene editing have been developed [2]. We previously reported a rapid and efficient method for generating multigene-knockout HeLa cells using a simple CRISPR-Cas9 system, in which at least seven genes can be simultaneously knocked out by co-transfection of multiple sgRNA-expressing plasmids [3,4]. In principle, this method can be applied to other cell lines; however, transfection efficiency may be limiting for certain cell types, particularly hematopoietic cell lines. For example, the widely used human monocytic leukemia cell line THP-1 is a hard-to-transfect suspension cell line, and several reports describe protocols for efficient THP-1 transfection by electroporation [5,6], cationic lipids [7], and lentiviral vectors [8]. Recently, two groups reported protocols to efficiently generate single-gene knockout THP-1 cells using lentiviral vectors [9,10]. Lentiviral methods are useful for many applications, including multiplex knockout and library screening, but establishing a non-viral multiplex knockout system that does not integrate into the genome remains challenging. Here, we provide step-by-step protocols for generating multigene-knockout THP-1 cells by electroporation using multiple targeting plasmids, each expressing a single-guide RNA (sgRNA) and engineered Cas9. To ensure that the transfected cells express all the sgRNA genes, cells are co-transfected with the plasmid mixture and a small amount of the pUREF-EX plasmid by electroporation. Then, cells are selected using an extremely high concentration of puromycin to enrich for cells that incorporate high-copy-number plasmids. Although we previously described a concise procedure for generating multigene-knockout polyclonal cell lines from HeLa cells [3], a detailed protocol and technical tips tailored to THP-1 cells are beneficial when applying this method to other cell types. The protocol is validated with a case of multiple knockouts of seven genes in the Jun/Fos family. Method details Materials and reagents THP-1 cells (ATCC: TIB-202) were maintained in Growth Medium [GM = RPMI-1640 medium (Nacalai Tesque) supplemented with 10% fetal calf serum (Biosera), 50 µM 2-mercaptoethanol, 100 U/mL penicillin G (FujiFilm Wako), and 100 µg/mL streptomycin (FujiFilm Wako)] under a 5% CO2 atmosphere. Puromycin was purchased from InvivoGen. Electroporation was performed using the Neon™ Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) and the Neon™ Transfection System Kit (100 µL; MPK10096) according to the manufacturer’s protocol. The rabbit monoclonal antibodies used for Western blot were purchased from Cell Signaling Technology: c-Jun (#9165), JunB (#3753), JunD (#5000), c-Fos (#2250), FosB (#2251), Fra1 (#5281), and Fra2 (#19,967). Horseradish peroxidase (HRP)-conjugated swine anti-rabbit immunoglobulin antibody (Agilent Dako, P039901–2) and HRP-conjugated goat anti-rabbit immunoglobulin antibody (Cell Signaling Technology, #7074) were used as secondary antibodies. HRP-conjugated rabbit anti-β-actin antibody was purchased from MBL Life Science. Plasmid construction and preparation of the plasmid mixtures Targeting plasmids for the Cas9- and sgRNA-mediated gene knockout were constructed by inserting each 20-nucleotide target sequence into the BbsI site of the pX330-U6-Chimeric_BB-CBh-hSpCas9 (hereafter, pX330) plasmid [11](Addgene ID: 42,230). The target sequences listed in Table 1 were selected from the target entries of the GeCKOv2 human library [12,13] based on rankings from the CHOPCHOP web tool [14](https://chopchop.cbu.uib.no). For the construction of a targeting plasmid, sense (SN) and antisense (AS) 24- or 25-mer oligonucleotides (Table 2) were annealed to form double-stranded DNA and ligated to the BbsI-digested pX330 plasmid. Correct construction of the plasmids was confirmed by sequencing the insertion site. The pUREF-EX (Addgene ID: 199,331) plasmid was previously described [3].Table 1Target sequences for the CRISPR-Cas9 knockout.GeneHGNC NameChromosomeName of PlasmidTarget sequence (5′->3′)PAMc-JunJUNChr.1p32.1pX330-Jun-TG1⁎gTCGTTCCTCCCGTCCGAGAGCGGpX330-Jun-TG2gCACGCTGCCCAGCGTCACGTCGGJunBJUNBChr.19p13.13pX330-JunB-TG1⁎gCACGACGACGCCTACACCCCCGGpX330-JunB-TG2⁎GTACGAGCTCCCGGTCCCGACGGJunDJUNDChr.19p13.11pX330-JunD-TG1⁎gTTCGCGTAGACAGGCGCTTCGGGpX330-JunD-TG2GGCGGGCTCTCGCCGAAGCTCGGc-FosFOSChr.14q24.3pX330-Fos-TG1⁎GGCGTTGTGAAGACCATGACAGGpX330-Fos-TG2gCTGCAGCCAAATGCCGCAACCGGFosBFOSBChr.19q13.32pX330-FosB-TG1⁎gCGTCGACCCCTACGACATGCCGGpX330-FosB-TG2gCCGTAGGAGTGCGCCGGTCTCGGFra1FOSL1Chr.11q13.1pX330-Fra1-TG1⁎gCGCCTCCAGGGGTACGTCGAAGGpX330-Fra1-TG2GGCCGGGTTCCCCGAAGTCTCGGFra2FOSL2Chr.2p23.2pX330-Fra2-TG1⁎gAGTGTGCAAGATTAGCCCCGAGGpX330-Fra2-TG2gCCTGGCGTGATCAAGACCATTGGThe lower-case "g" in the 5′ end is an extra nucleotide added for efficient transcription.⁎The asterisks indicate targeting plasmids used in this study.Table 2Oligonucleotides used for the plasmid construction.TargetSense oligonucleotidesAntisense oligonucleotidesJun-TG1caccgTCGTTCCTCCCGTCCGAGAGaaacCTCTCGGACGGGAGGAACGAcJunB-TG1caccgCACGACGACGCCTACACCCCaaacGGGGTGTAGGCGTCGTCGTGcJunB-TG2caccGTACGAGCTCCCGGTCCCGAaaacTCGGGACCGGGAGCTCGTACJunD-TG1caccgTTCGCGTAGACAGGCGCTTCaaacGAAGCGCCTGTCTACGCGAAcFos-TG1caccGGCGTTGTGAAGACCATGACaaacGTCATGGTCTTCACAACGCCFosB-TG1caccgCGTCGACCCCTACGACATGCaaacGCATGTCGTAGGGGTCGACGcFra1-TG1caccgCGCCTCCAGGGGTACGTCGAaaacTCGACGTACCCCTGGAGGCGcFra2-TG1caccgAGTGTGCAAGATTAGCCCCGaaacCGGGGCTAATCTTGCACACTc Table 1Target sequences for the CRISPR-Cas9 knockout.GeneHGNC NameChromosomeName of PlasmidTarget sequence (5′->3′)PAMc-JunJUNChr.1p32.1pX330-Jun-TG1⁎gTCGTTCCTCCCGTCCGAGAGCGGpX330-Jun-TG2gCACGCTGCCCAGCGTCACGTCGGJunBJUNBChr.19p13.13pX330-JunB-TG1⁎gCACGACGACGCCTACACCCCCGGpX330-JunB-TG2⁎GTACGAGCTCCCGGTCCCGACGGJunDJUNDChr.19p13.11pX330-JunD-TG1⁎gTTCGCGTAGACAGGCGCTTCGGGpX330-JunD-TG2GGCGGGCTCTCGCCGAAGCTCGGc-FosFOSChr.14q24.3pX330-Fos-TG1⁎GGCGTTGTGAAGACCATGACAGGpX330-Fos-TG2gCTGCAGCCAAATGCCGCAACCGGFosBFOSBChr.19q13.32pX330-FosB-TG1⁎gCGTCGACCCCTACGACATGCCGGpX330-FosB-TG2gCCGTAGGAGTGCGCCGGTCTCGGFra1FOSL1Chr.11q13.1pX330-Fra1-TG1⁎gCGCCTCCAGGGGTACGTCGAAGGpX330-Fra1-TG2GGCCGGGTTCCCCGAAGTCTCGGFra2FOSL2Chr.2p23.2pX330-Fra2-TG1⁎gAGTGTGCAAGATTAGCCCCGAGGpX330-Fra2-TG2gCCTGGCGTGATCAAGACCATTGGThe lower-case "g" in the 5′ end is an extra nucleotide added for efficient transcription.⁎The asterisks indicate targeting plasmids used in this study. Target sequences for the CRISPR-Cas9 knockout. The lower-case "g" in the 5′ end is an extra nucleotide added for efficient transcription. The asterisks indicate targeting plasmids used in this study. Table 2Oligonucleotides used for the plasmid construction.TargetSense oligonucleotidesAntisense oligonucleotidesJun-TG1caccgTCGTTCCTCCCGTCCGAGAGaaacCTCTCGGACGGGAGGAACGAcJunB-TG1caccgCACGACGACGCCTACACCCCaaacGGGGTGTAGGCGTCGTCGTGcJunB-TG2caccGTACGAGCTCCCGGTCCCGAaaacTCGGGACCGGGAGCTCGTACJunD-TG1caccgTTCGCGTAGACAGGCGCTTCaaacGAAGCGCCTGTCTACGCGAAcFos-TG1caccGGCGTTGTGAAGACCATGACaaacGTCATGGTCTTCACAACGCCFosB-TG1caccgCGTCGACCCCTACGACATGCaaacGCATGTCGTAGGGGTCGACGcFra1-TG1caccgCGCCTCCAGGGGTACGTCGAaaacTCGACGTACCCCTGGAGGCGcFra2-TG1caccgAGTGTGCAAGATTAGCCCCGaaacCGGGGCTAATCTTGCACACTc Oligonucleotides used for the plasmid construction. All plasmids were propagated in Escherichia coli DH5α, purified using the NucleoBond Xtra Midi kit (Macherey-Nagel, Takara), and dissolved in Tris-EDTA buffer (TE = 10 mM Tris–HCl and 1 mM EDTA, pH 8.0) at a concentration of 0.5 mg/mL. For electroporation, 1.5 µL (0.75 µg) of pUREF-EX and 20 µL (10 µg) in total of an equal amount of pX330-derived plasmids [e.g., 5 µL (2.5 µg) each of four types of pX330-derived plasmids for quadruple knockout] were mixed to prepare a 21.5 µL mixture containing a total of 10.75 µg of plasmids, as shown in Table 3.Table 3Co-transfected plasmids for generating Jun/Fos-multigene KO cells.KO cellspUREF-EXpX330-EmptyJun-TG1JunB-TG1JunB-TG2JunD-TG1Fos-TG1FosB-TG1Fra1-TG1Fra2-TG1Negative control--2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µLVector control1.5 μL20 µL--------Jun-TKO1.5 μL-5 µL5 µL5 µL5 µL----Fos-QKO1.5 μL-----5 µL5 µL5 µL5 µLJunFos-SKO1.5 μL-2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µLc-Jun-ss-HKO1.5 μL--2.86 µL2.86 µL2.86 µL2.86 µL2.86 µL2.86 µL2.86 µLc-Fos-ss-HKO1.5 μL-2.86 µL2.86 µL2.86 µL2.86 µL-2.86 µL2.86 µL2.86 µLAll plasmids were prepared at 0.5 mg/mL in TE buffer. Table 3Co-transfected plasmids for generating Jun/Fos-multigene KO cells.KO cellspUREF-EXpX330-EmptyJun-TG1JunB-TG1JunB-TG2JunD-TG1Fos-TG1FosB-TG1Fra1-TG1Fra2-TG1Negative control--2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µLVector control1.5 μL20 µL--------Jun-TKO1.5 μL-5 µL5 µL5 µL5 µL----Fos-QKO1.5 μL-----5 µL5 µL5 µL5 µLJunFos-SKO1.5 μL-2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µL2.5 µLc-Jun-ss-HKO1.5 μL--2.86 µL2.86 µL2.86 µL2.86 µL2.86 µL2.86 µL2.86 µLc-Fos-ss-HKO1.5 μL-2.86 µL2.86 µL2.86 µL2.86 µL-2.86 µL2.86 µL2.86 µLAll plasmids were prepared at 0.5 mg/mL in TE buffer. Co-transfected plasmids for generating Jun/Fos-multigene KO cells. All plasmids were prepared at 0.5 mg/mL in TE buffer. Western blot analysis One million THP-1 or THP-1-derived KO cells were incubated in 1 mL of GM containing 0.5% calf serum instead of fetal calf serum at 37 °C for 18 h for serum starvation. Then, cells were left unstimulated (-) or stimulated with 0.5–1.0 µM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, P8139) or 100 ng/mL lipopolysaccharide (LPS; Sigma-Aldrich, L4391) at 37 °C for 120 min. Cells were washed with 1 mL of ice-cold phosphate-buffered saline (PBS) containing 1 x Protease Inhibitor Cocktail for Use with Mammalian Cell and Tissue Extracts (Nacalai Tesque, #25,955), suspended in 20 µL of ice -cold PBS containing the same protease inhibitor cocktail. Cells were lysed with 80 µL of 1.25 x Laemmli's SDS sample buffer (1x buffer = 62.5 mM Tris–HCl [pH 6.8], 2% SDS, 10% glycerol, 5% 2-mercaptoethanol, and 0.01% bromophenol blue) with vigorous vortexing, incubated at 85 °C for 30 min to shear genomic DNA, and then at 95 °C for 5 min. Cell lysates were resolved by 12.5% SDS-polyacrylamide gel electrophoresis and analyzed by Western blotting with the ECL reagent set, Clarity Western ECL Substrate (Bio-Rad Laboratories), using the chemiluminescence imaging system LuminoGraph III (ATTO Corporation). The signal intensities of bands in Western blots were quantified using a CS analyzer 4 (ATTO Corporation). Protocol 1. transfection of THP-1 cells with a plasmid mixture by electroporation 1.Culture THP-1 cells in GM until the cell concentration reaches semi-confluence (1–1.5 × 106 cells/mL).2.Centrifuge the THP-1 cell suspension at 2000 rpm for 10 min at 4 °C.3.Remove the supernatant and suspend cells in 10 mL of ice-cold PBS, and centrifuge the cells at 2000 rpm for 10 min at 4 °C.4.Suspend the cells in ice-cold Resuspension Buffer R (Neon™ Transfection System Kit), and adjust the cell concentration to 2.0 × 107 cells/mL.5.Dispense 100 µL of the cell suspensions into the required number of 1.5 mL microcentrifuge tubes.6.Add 21.5 µL of a 0.5 mg/mL plasmid mixture in TE buffer (10.75 µg of plasmid DNA in total) into each tube.7.Gently mix the DNA/cell suspension with a 100 µL Neon Tip and take 100 µL of the suspension into the Neon Tip, avoiding any trapped air bubbles.8.Insert the Neon Tip into a Neon tube containing 3 mL of Buffer E2 on the Neon Pipet Station.9.Set the electroporation condition of the Neon Device to 1400 V, 20 ms, two pulses, and press the START button.10.Immediately transfer the cell suspension into a 100-mm culture dish containing 10 mL of prewarmed (at 37 °C), antibiotic-free GM (i.e., without penicillin G and streptomycin).11.Incubate the cell culture at 37 °C for 18 h in a CO2 incubator. 1.Culture THP-1 cells in GM until the cell concentration reaches semi-confluence (1–1.5 × 106 cells/mL). Culture THP-1 cells in GM until the cell concentration reaches semi-confluence (1–1.5 × 106 cells/mL). 2.Centrifuge the THP-1 cell suspension at 2000 rpm for 10 min at 4 °C. Centrifuge the THP-1 cell suspension at 2000 rpm for 10 min at 4 °C. 3.Remove the supernatant and suspend cells in 10 mL of ice-cold PBS, and centrifuge the cells at 2000 rpm for 10 min at 4 °C. Remove the supernatant and suspend cells in 10 mL of ice-cold PBS, and centrifuge the cells at 2000 rpm for 10 min at 4 °C. 4.Suspend the cells in ice-cold Resuspension Buffer R (Neon™ Transfection System Kit), and adjust the cell concentration to 2.0 × 107 cells/mL. Suspend the cells in ice-cold Resuspension Buffer R (Neon™ Transfection System Kit), and adjust the cell concentration to 2.0 × 107 cells/mL. 5.Dispense 100 µL of the cell suspensions into the required number of 1.5 mL microcentrifuge tubes. Dispense 100 µL of the cell suspensions into the required number of 1.5 mL microcentrifuge tubes. 6.Add 21.5 µL of a 0.5 mg/mL plasmid mixture in TE buffer (10.75 µg of plasmid DNA in total) into each tube. Add 21.5 µL of a 0.5 mg/mL plasmid mixture in TE buffer (10.75 µg of plasmid DNA in total) into each tube. 7.Gently mix the DNA/cell suspension with a 100 µL Neon Tip and take 100 µL of the suspension into the Neon Tip, avoiding any trapped air bubbles. Gently mix the DNA/cell suspension with a 100 µL Neon Tip and take 100 µL of the suspension into the Neon Tip, avoiding any trapped air bubbles. 8.Insert the Neon Tip into a Neon tube containing 3 mL of Buffer E2 on the Neon Pipet Station. Insert the Neon Tip into a Neon tube containing 3 mL of Buffer E2 on the Neon Pipet Station. 9.Set the electroporation condition of the Neon Device to 1400 V, 20 ms, two pulses, and press the START button. Set the electroporation condition of the Neon Device to 1400 V, 20 ms, two pulses, and press the START button. 10.Immediately transfer the cell suspension into a 100-mm culture dish containing 10 mL of prewarmed (at 37 °C), antibiotic-free GM (i.e., without penicillin G and streptomycin). Immediately transfer the cell suspension into a 100-mm culture dish containing 10 mL of prewarmed (at 37 °C), antibiotic-free GM (i.e., without penicillin G and streptomycin). 11.Incubate the cell culture at 37 °C for 18 h in a CO2 incubator. Incubate the cell culture at 37 °C for 18 h in a CO2 incubator. Protocol 2. transient selection with high-dose puromycin 1.Add 10 µL of 10 mg/mL puromycin to the transfected cell culture (i.e., final concentration of 10 µg/mL).2.Incubate the cell culture at 37 °C for 24 h.3.Observe the cells under a microscope and confirm that almost all cells are dead and that viable cells are scarcely observed.4.Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4°C.5.Aspirate approximately 9 mL of the supernatant, leaving the cell pellet with approximately 1 mL of the residual medium in the tube.6.Add 9 mL of fresh GM to the tube to adjust the final puromycin concentration to approximately 1 µg/mL.7.Transfer the cell suspension back into the original 100-mm dish.8.Incubate the cell culture at 37 °C for 24 h.9.Transfer the cells into a 15-ml tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C.10.Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet.11.Resuspend the cells in 10 mL of fresh GM and transfer the cell suspension into a fresh 100-mm dish.12.Incubate the cell culture at 37 °C for 24 h.13.Gently transfer the culture dishes to the laminar flow clean bench, avoiding suspending the sedimented cells.14.Carefully aspirate approximately half of the culture medium from the surface of the medium and add 6 mL of fresh GM.15.Perform the partial medium change every 3–4 days as described above, and maintain the culture until the concentration of viable cells exceeds that of dead cells (approximately 0.5–1 × 105 cells/mL).16.Transfer the cells to fresh culture medium by 2–20-fold dilution before cell concentration reaches confluence (1–2 × 106 cells/mL).17.Prepare cell lysate or genomic DNA to check knockout efficiency and frozen stocks of each KO cell line. 1.Add 10 µL of 10 mg/mL puromycin to the transfected cell culture (i.e., final concentration of 10 µg/mL). Add 10 µL of 10 mg/mL puromycin to the transfected cell culture (i.e., final concentration of 10 µg/mL). 2.Incubate the cell culture at 37 °C for 24 h. Incubate the cell culture at 37 °C for 24 h. 3.Observe the cells under a microscope and confirm that almost all cells are dead and that viable cells are scarcely observed. Observe the cells under a microscope and confirm that almost all cells are dead and that viable cells are scarcely observed. 4.Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4°C. Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4°C. 5.Aspirate approximately 9 mL of the supernatant, leaving the cell pellet with approximately 1 mL of the residual medium in the tube. Aspirate approximately 9 mL of the supernatant, leaving the cell pellet with approximately 1 mL of the residual medium in the tube. 6.Add 9 mL of fresh GM to the tube to adjust the final puromycin concentration to approximately 1 µg/mL. Add 9 mL of fresh GM to the tube to adjust the final puromycin concentration to approximately 1 µg/mL. 7.Transfer the cell suspension back into the original 100-mm dish. Transfer the cell suspension back into the original 100-mm dish. 8.Incubate the cell culture at 37 °C for 24 h. Incubate the cell culture at 37 °C for 24 h. 9.Transfer the cells into a 15-ml tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C. Transfer the cells into a 15-ml tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C. 10.Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet. Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet. 11.Resuspend the cells in 10 mL of fresh GM and transfer the cell suspension into a fresh 100-mm dish. Resuspend the cells in 10 mL of fresh GM and transfer the cell suspension into a fresh 100-mm dish. 12.Incubate the cell culture at 37 °C for 24 h. Incubate the cell culture at 37 °C for 24 h. 13.Gently transfer the culture dishes to the laminar flow clean bench, avoiding suspending the sedimented cells. Gently transfer the culture dishes to the laminar flow clean bench, avoiding suspending the sedimented cells. 14.Carefully aspirate approximately half of the culture medium from the surface of the medium and add 6 mL of fresh GM. Carefully aspirate approximately half of the culture medium from the surface of the medium and add 6 mL of fresh GM. 15.Perform the partial medium change every 3–4 days as described above, and maintain the culture until the concentration of viable cells exceeds that of dead cells (approximately 0.5–1 × 105 cells/mL). Perform the partial medium change every 3–4 days as described above, and maintain the culture until the concentration of viable cells exceeds that of dead cells (approximately 0.5–1 × 105 cells/mL). 16.Transfer the cells to fresh culture medium by 2–20-fold dilution before cell concentration reaches confluence (1–2 × 106 cells/mL). Transfer the cells to fresh culture medium by 2–20-fold dilution before cell concentration reaches confluence (1–2 × 106 cells/mL). 17.Prepare cell lysate or genomic DNA to check knockout efficiency and frozen stocks of each KO cell line. Prepare cell lysate or genomic DNA to check knockout efficiency and frozen stocks of each KO cell line. Protocol 3 (optional): cloning by limiting dilution The knockout efficiency of the above protocol is generally high enough for applying the polyclonal knockout cells to subsequent experiments. In some cases, however, targeted disruption of a gene important for cell proliferation may slow proliferation of knockout cells, causing them to disappear from the polyclonal cell population after propagation, since the polyclonal cell lines generated as above contain some, if not many, non-knockout cells with a higher growth rate. To avoid dropout of slowly growing knockout cells, isolate knockout clones soon after puromycin selection.1.Carry out the transfection and puromycin selection up to step 12 of Protocol 2.2.Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C.3.Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet.4.Add 1 mL of fresh GM and resuspend the cells by repeated pipetting to resolve cell aggregation completely.5.Count the viable cells if possible and dilute them with GM to prepare 47.4 mL of a 200 cells/mL cell suspension in a 50-mL tube. This is Suspension A (Susp. A). If the number of viable cells is too low for accurate counting, just dilute the original cell suspension to a final volume of 47.4 mL.6.Transfer 15 mL of Susp. A to a new 50-mL tube, add 32.4 mL of fresh GM, and mix. This is Susp. B (47.4 mL).7.Repeat the same dilution handling to make 6 tubes of 3.16 (c.a. 10)-fold serial dilutions (each 32.4 mL) from 200 cells/mL (Susp. A) to 0.632 cells/mL (Susp. F, 47.4 mL).8.Dispense 150 µL of Susp. A into each well of two 96-well microtiter plates. Repeat the same handling for all the serial dilutions, Susp. B to Susp. F. This means the cell concentration ranges from approximately 30 to 0.1 cells/well. Three plates may be used for Susp. F.9.Incubate the cell culture at 37 °C for 10–20 days until clusters of growing cells become sufficiently large (> 103 cells) in positive wells. Maintain saturated humidity in the CO2 incubator to prevent evaporation of the culture medium throughout this period.10.Select plates containing fewer than 30 cluster-positive wells. From these plates, transfer cells in each positive well to a well in a 24- or 12-well plate. In principle, each well should contain a clonal cell population with a probability greater than 85%.11.Propagate the clones and prepare their cell lysate or genomic DNA to check whether the isolated cells are knockout clones or not. 1.Carry out the transfection and puromycin selection up to step 12 of Protocol 2. Carry out the transfection and puromycin selection up to step 12 of Protocol 2. 2.Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C. Transfer the cells into a 15-mL tube and centrifuge the tube at 2000 rpm for 10 min at 4 °C. 3.Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet. Carefully aspirate the supernatant, taking great care not to lose any of the cell pellet. 4.Add 1 mL of fresh GM and resuspend the cells by repeated pipetting to resolve cell aggregation completely. Add 1 mL of fresh GM and resuspend the cells by repeated pipetting to resolve cell aggregation completely. 5.Count the viable cells if possible and dilute them with GM to prepare 47.4 mL of a 200 cells/mL cell suspension in a 50-mL tube. This is Suspension A (Susp. A). If the number of viable cells is too low for accurate counting, just dilute the original cell suspension to a final volume of 47.4 mL. Count the viable cells if possible and dilute them with GM to prepare 47.4 mL of a 200 cells/mL cell suspension in a 50-mL tube. This is Suspension A (Susp. A). If the number of viable cells is too low for accurate counting, just dilute the original cell suspension to a final volume of 47.4 mL. 6.Transfer 15 mL of Susp. A to a new 50-mL tube, add 32.4 mL of fresh GM, and mix. This is Susp. B (47.4 mL). Transfer 15 mL of Susp. A to a new 50-mL tube, add 32.4 mL of fresh GM, and mix. This is Susp. B (47.4 mL). 7.Repeat the same dilution handling to make 6 tubes of 3.16 (c.a. 10)-fold serial dilutions (each 32.4 mL) from 200 cells/mL (Susp. A) to 0.632 cells/mL (Susp. F, 47.4 mL). Repeat the same dilution handling to make 6 tubes of 3.16 (c.a. 10)-fold serial dilutions (each 32.4 mL) from 200 cells/mL (Susp. A) to 0.632 cells/mL (Susp. F, 47.4 mL). 8.Dispense 150 µL of Susp. A into each well of two 96-well microtiter plates. Repeat the same handling for all the serial dilutions, Susp. B to Susp. F. This means the cell concentration ranges from approximately 30 to 0.1 cells/well. Three plates may be used for Susp. F. Dispense 150 µL of Susp. A into each well of two 96-well microtiter plates. Repeat the same handling for all the serial dilutions, Susp. B to Susp. F. This means the cell concentration ranges from approximately 30 to 0.1 cells/well. Three plates may be used for Susp. F. 9.Incubate the cell culture at 37 °C for 10–20 days until clusters of growing cells become sufficiently large (> 103 cells) in positive wells. Maintain saturated humidity in the CO2 incubator to prevent evaporation of the culture medium throughout this period. Incubate the cell culture at 37 °C for 10–20 days until clusters of growing cells become sufficiently large (> 103 cells) in positive wells. Maintain saturated humidity in the CO2 incubator to prevent evaporation of the culture medium throughout this period. 10.Select plates containing fewer than 30 cluster-positive wells. From these plates, transfer cells in each positive well to a well in a 24- or 12-well plate. In principle, each well should contain a clonal cell population with a probability greater than 85%. Select plates containing fewer than 30 cluster-positive wells. From these plates, transfer cells in each positive well to a well in a 24- or 12-well plate. In principle, each well should contain a clonal cell population with a probability greater than 85%. 11.Propagate the clones and prepare their cell lysate or genomic DNA to check whether the isolated cells are knockout clones or not. Propagate the clones and prepare their cell lysate or genomic DNA to check whether the isolated cells are knockout clones or not. Technical tips •Before transfection, optimize electroporation conditions for the cells you use, as they depend critically on the cell type and the electroporation device. We used the Neon Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) for THP-1 cells. According to the manufacturer’s instructions, we determined the electric pulse conditions (1400 V, 20 ms, 2 pulses), cell density (2.0 × 107 cells/mL), and total plasmid amount (10.75 µg) for a 100 µL Neon Tip, by measuring luciferase activity of the cell extract prepared from the THP-1 cells transfected with a firefly luciferase reporter plasmid. We estimated the transfection efficiency under these conditions by transfecting an EGFP-expressing plasmid; about 70% of live cells were GFP-positive 24 h after electroporation.•After transfection, we selected cells using an extremely high concentration of puromycin (10 µg/mL), >10 times the standard concentration. This transient, high-dose drug selection would enrich for cells that incorporate relatively high plasmid copy numbers. Therefore, determine the puromycin concentration for transient selection of the cells you use. We first determined the minimum puromycin concentration required to select THP-1 cells using GM containing 0, 0.1, 0.316, 1.0, 3.16, and 10 µg/mL puromycin. THP-1 cells died almost completely within 48 h in the medium containing 1.0 µg/mL puromycin, whereas they died only partially in the medium containing 0.316 µg/mL puromycin. This indicates that 1.0 µg/mL would be suitable for most experiments to select for puromycin-resistant stable transformants. Next, we tested 1, 5, and 10 µg/mL puromycin in pilot knockout experiments and found that transient selection with 10 µg/mL puromycin effectively generated multigene knockout cells. We have not tested a higher puromycin concentration.•Based on our experience, the ratio of pUREF-EX to the targeting plasmid mixture may be set between 1:10 and 1:20, which is likely to yield appropriate results.•After the puromycin selection (Protocol 2, Step 3), almost all cells will die, but a very small number of cells are expected to remain alive. If the transfection is successful, the living cells will be clearly visible in the relevant cultures 8 to 12 days after the puromycin selection. No living cells should be visible in the negative control culture of cells transfected without pUREF-EX (Table 3). •Before transfection, optimize electroporation conditions for the cells you use, as they depend critically on the cell type and the electroporation device. We used the Neon Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) for THP-1 cells. According to the manufacturer’s instructions, we determined the electric pulse conditions (1400 V, 20 ms, 2 pulses), cell density (2.0 × 107 cells/mL), and total plasmid amount (10.75 µg) for a 100 µL Neon Tip, by measuring luciferase activity of the cell extract prepared from the THP-1 cells transfected with a firefly luciferase reporter plasmid. We estimated the transfection efficiency under these conditions by transfecting an EGFP-expressing plasmid; about 70% of live cells were GFP-positive 24 h after electroporation.•After transfection, we selected cells using an extremely high concentration of puromycin (10 µg/mL), >10 times the standard concentration. This transient, high-dose drug selection would enrich for cells that incorporate relatively high plasmid copy numbers. Therefore, determine the puromycin concentration for transient selection of the cells you use. We first determined the minimum puromycin concentration required to select THP-1 cells using GM containing 0, 0.1, 0.316, 1.0, 3.16, and 10 µg/mL puromycin. THP-1 cells died almost completely within 48 h in the medium containing 1.0 µg/mL puromycin, whereas they died only partially in the medium containing 0.316 µg/mL puromycin. This indicates that 1.0 µg/mL would be suitable for most experiments to select for puromycin-resistant stable transformants. Next, we tested 1, 5, and 10 µg/mL puromycin in pilot knockout experiments and found that transient selection with 10 µg/mL puromycin effectively generated multigene knockout cells. We have not tested a higher puromycin concentration.•Based on our experience, the ratio of pUREF-EX to the targeting plasmid mixture may be set between 1:10 and 1:20, which is likely to yield appropriate results.•After the puromycin selection (Protocol 2, Step 3), almost all cells will die, but a very small number of cells are expected to remain alive. If the transfection is successful, the living cells will be clearly visible in the relevant cultures 8 to 12 days after the puromycin selection. No living cells should be visible in the negative control culture of cells transfected without pUREF-EX (Table 3). •Before transfection, optimize electroporation conditions for the cells you use, as they depend critically on the cell type and the electroporation device. We used the Neon Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) for THP-1 cells. According to the manufacturer’s instructions, we determined the electric pulse conditions (1400 V, 20 ms, 2 pulses), cell density (2.0 × 107 cells/mL), and total plasmid amount (10.75 µg) for a 100 µL Neon Tip, by measuring luciferase activity of the cell extract prepared from the THP-1 cells transfected with a firefly luciferase reporter plasmid. We estimated the transfection efficiency under these conditions by transfecting an EGFP-expressing plasmid; about 70% of live cells were GFP-positive 24 h after electroporation.•After transfection, we selected cells using an extremely high concentration of puromycin (10 µg/mL), >10 times the standard concentration. This transient, high-dose drug selection would enrich for cells that incorporate relatively high plasmid copy numbers. Therefore, determine the puromycin concentration for transient selection of the cells you use. We first determined the minimum puromycin concentration required to select THP-1 cells using GM containing 0, 0.1, 0.316, 1.0, 3.16, and 10 µg/mL puromycin. THP-1 cells died almost completely within 48 h in the medium containing 1.0 µg/mL puromycin, whereas they died only partially in the medium containing 0.316 µg/mL puromycin. This indicates that 1.0 µg/mL would be suitable for most experiments to select for puromycin-resistant stable transformants. Next, we tested 1, 5, and 10 µg/mL puromycin in pilot knockout experiments and found that transient selection with 10 µg/mL puromycin effectively generated multigene knockout cells. We have not tested a higher puromycin concentration.•Based on our experience, the ratio of pUREF-EX to the targeting plasmid mixture may be set between 1:10 and 1:20, which is likely to yield appropriate results.•After the puromycin selection (Protocol 2, Step 3), almost all cells will die, but a very small number of cells are expected to remain alive. If the transfection is successful, the living cells will be clearly visible in the relevant cultures 8 to 12 days after the puromycin selection. No living cells should be visible in the negative control culture of cells transfected without pUREF-EX (Table 3). •Before transfection, optimize electroporation conditions for the cells you use, as they depend critically on the cell type and the electroporation device. We used the Neon Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) for THP-1 cells. According to the manufacturer’s instructions, we determined the electric pulse conditions (1400 V, 20 ms, 2 pulses), cell density (2.0 × 107 cells/mL), and total plasmid amount (10.75 µg) for a 100 µL Neon Tip, by measuring luciferase activity of the cell extract prepared from the THP-1 cells transfected with a firefly luciferase reporter plasmid. We estimated the transfection efficiency under these conditions by transfecting an EGFP-expressing plasmid; about 70% of live cells were GFP-positive 24 h after electroporation. Before transfection, optimize electroporation conditions for the cells you use, as they depend critically on the cell type and the electroporation device. We used the Neon Transfection System Unit MPK5000 (Invitrogen, Thermo Fisher) for THP-1 cells. According to the manufacturer’s instructions, we determined the electric pulse conditions (1400 V, 20 ms, 2 pulses), cell density (2.0 × 107 cells/mL), and total plasmid amount (10.75 µg) for a 100 µL Neon Tip, by measuring luciferase activity of the cell extract prepared from the THP-1 cells transfected with a firefly luciferase reporter plasmid. We estimated the transfection efficiency under these conditions by transfecting an EGFP-expressing plasmid; about 70% of live cells were GFP-positive 24 h after electroporation. •After transfection, we selected cells using an extremely high concentration of puromycin (10 µg/mL), >10 times the standard concentration. This transient, high-dose drug selection would enrich for cells that incorporate relatively high plasmid copy numbers. Therefore, determine the puromycin concentration for transient selection of the cells you use. We first determined the minimum puromycin concentration required to select THP-1 cells using GM containing 0, 0.1, 0.316, 1.0, 3.16, and 10 µg/mL puromycin. THP-1 cells died almost completely within 48 h in the medium containing 1.0 µg/mL puromycin, whereas they died only partially in the medium containing 0.316 µg/mL puromycin. This indicates that 1.0 µg/mL would be suitable for most experiments to select for puromycin-resistant stable transformants. Next, we tested 1, 5, and 10 µg/mL puromycin in pilot knockout experiments and found that transient selection with 10 µg/mL puromycin effectively generated multigene knockout cells. We have not tested a higher puromycin concentration. After transfection, we selected cells using an extremely high concentration of puromycin (10 µg/mL), >10 times the standard concentration. This transient, high-dose drug selection would enrich for cells that incorporate relatively high plasmid copy numbers. Therefore, determine the puromycin concentration for transient selection of the cells you use. We first determined the minimum puromycin concentration required to select THP-1 cells using GM containing 0, 0.1, 0.316, 1.0, 3.16, and 10 µg/mL puromycin. THP-1 cells died almost completely within 48 h in the medium containing 1.0 µg/mL puromycin, whereas they died only partially in the medium containing 0.316 µg/mL puromycin. This indicates that 1.0 µg/mL would be suitable for most experiments to select for puromycin-resistant stable transformants. Next, we tested 1, 5, and 10 µg/mL puromycin in pilot knockout experiments and found that transient selection with 10 µg/mL puromycin effectively generated multigene knockout cells. We have not tested a higher puromycin concentration. •Based on our experience, the ratio of pUREF-EX to the targeting plasmid mixture may be set between 1:10 and 1:20, which is likely to yield appropriate results. Based on our experience, the ratio of pUREF-EX to the targeting plasmid mixture may be set between 1:10 and 1:20, which is likely to yield appropriate results. •After the puromycin selection (Protocol 2, Step 3), almost all cells will die, but a very small number of cells are expected to remain alive. If the transfection is successful, the living cells will be clearly visible in the relevant cultures 8 to 12 days after the puromycin selection. No living cells should be visible in the negative control culture of cells transfected without pUREF-EX (Table 3). After the puromycin selection (Protocol 2, Step 3), almost all cells will die, but a very small number of cells are expected to remain alive. If the transfection is successful, the living cells will be clearly visible in the relevant cultures 8 to 12 days after the puromycin selection. No living cells should be visible in the negative control culture of cells transfected without pUREF-EX (Table 3). Method validation The AP-1 transcription factor is a dimeric complex consisting of two bZIP proteins, the Jun and Fos families of which have been extensively studied [15]. We first attempted to generate single-gene-knockout HeLa cells for each of the seven family members, c-Jun, JunB, JunD, c-Fos, FosB, Fra1, and Fra2, to evaluate the knockout efficiencies of targeting plasmids. We constructed two targeting plasmids, TG1 and TG2, for each of the seven genes (Table 1) and tested their knockout efficiencies in HeLa cells by Western blotting, as described [3]. Expression of the protein from each targeted gene was strongly reduced to scarcely detectable levels in HeLa-derived cell lines, except for cell lines of JunB-TG1, JunB-TG2, FosB-TG2, and Fra2-TG2 (data not shown). Then, we attempted to generate multiplex gene knockout cell lines from THP-1 cells, including c-Jun/JunB/JunD-triple KO (Jun-TKO), c-Fos/FosB/Fra1/Fra2-quadruple KO (Fos-QKO), and c-Jun/JunB/JunD/c-Fos/FosB/Fra1/Fra2-septuple KO (JunFos-SKO), by co-transfecting THP-1 cells with mixtures of the targeting plasmids (Table 3), as illustrated in the Graphical Abstract. For the JunB-KO, we used a combination of the pX330-JunB-TG1 and -TG2 plasmids to attain high KO efficiency. We also generated the sole-survivor (ss)-KO cells, in which only one of the seven Jun/Fos genes remains undisrupted. For example, the JunB/JunD/c-Fos/FosB/Fra1/Fra2-hextuple KO (HKO) cells were designated as c-Jun-ss-HKO cells (Table 3). THP-1 cells were transfected and puromycin-selected as described in Protocols 1 and 2, and the whole-cell lysates were analyzed by Western blotting (Fig. 1). In the vector control cells (Vector), c-Jun and c-Fos were inducibly expressed by stimulation with PMA, whereas JunB, JunD, FosB, Fra1, and Fra2 showed basal expression and PMA- or LPS-induced upregulation. In contrast, expression of the Jun family members was scarcely detectable in Jun-TKO and JunFos-SKO polyclonal cells. Expression of Fos family members was drastically reduced in Fos-QKO and JunFos-SKO polyclonal cells. The c-Jun-ss-HKO and c-Fos-ss-HKO cell lines expressed non-targeted genes but showed low or undetectable expression of the targeted genes. A rough estimate of knockout efficiency by densitometric analysis of the bands in the Western blots indicated that protein expression from the targeted genes in these polyclonal knockout cells was reduced to about one-fifth or less compared with the vector control cells, except that c-Jun appeared to be expressed at significant levels in JunFos-SKO and c-Fos-ss-HKO cells (Table 4).Fig. 1Simultaneous multiplex gene KO of Jun/Fos family members in THP-1 cells. Vector-control and various Jun/Fos-KO cell lines generated by the plasmid combinations indicated in Table 3 were either unstimulated (-) or stimulated with 1 µM PMA or 100 ng/mL LPS for 120 min. Whole-cell lysates were prepared and subjected to Western blot analysis using specific antibodies against c-Jun, JunB, JunD, c-Fos, FosB, Fra1, and Fra2 as described in the Method detail section. A Western blot of β-actin was used as a loading control.Table 4Semi-quantitative estimation of band intensities in western blotting.VectorJun-TKOFos-QKOJunFos-SKOc-Jun-ss-HKOc-Fos-ss-HKOc-Jun100.016.7193.726.0335.155.0JunB100.00.994.20.60.20.1JunD100.04.5100.910.83.67.2c-Fos100.0157.36.47.617.5173.1FosB100.069.32.31.71.65.0Fra1100.048.318.29.37.912.6Fra2100.058.311.91.65.56.0The signal intensities of the bands in each of the PMA-stimulated cells in Fig. 1 were quantified, normalized to those of the β-actin loading control, and expressed as percentages of the signal intensities in the vector control cells. Simultaneous multiplex gene KO of Jun/Fos family members in THP-1 cells. Vector-control and various Jun/Fos-KO cell lines generated by the plasmid combinations indicated in Table 3 were either unstimulated (-) or stimulated with 1 µM PMA or 100 ng/mL LPS for 120 min. Whole-cell lysates were prepared and subjected to Western blot analysis using specific antibodies against c-Jun, JunB, JunD, c-Fos, FosB, Fra1, and Fra2 as described in the Method detail section. A Western blot of β-actin was used as a loading control. Table 4Semi-quantitative estimation of band intensities in western blotting.VectorJun-TKOFos-QKOJunFos-SKOc-Jun-ss-HKOc-Fos-ss-HKOc-Jun100.016.7193.726.0335.155.0JunB100.00.994.20.60.20.1JunD100.04.5100.910.83.67.2c-Fos100.0157.36.47.617.5173.1FosB100.069.32.31.71.65.0Fra1100.048.318.29.37.912.6Fra2100.058.311.91.65.56.0The signal intensities of the bands in each of the PMA-stimulated cells in Fig. 1 were quantified, normalized to those of the β-actin loading control, and expressed as percentages of the signal intensities in the vector control cells. Semi-quantitative estimation of band intensities in western blotting. The signal intensities of the bands in each of the PMA-stimulated cells in Fig. 1 were quantified, normalized to those of the β-actin loading control, and expressed as percentages of the signal intensities in the vector control cells. No apparent differences in growth rate or cellular morphology were observed among wild-type THP-1, Vector control, Jun-TKO, and c-Fos-ss-HKO cells. However, Fos-QKO, JunFos-SKO, and c-Jun-ss-HKO cells appeared to grow more slowly than the others, and their growth rates gradually recovered after several weeks of continuous passage. This observation suggests that non-knockout cells, initially present in relatively small numbers within these polyclonal KO cell lines, might gradually increase their proportion, indicating that these polyclonal cell lines should not be used for any further experiments. Therefore, we used the method described in Protocol 3 to isolate clones from the Fos-QKO and JunFos-SKO cell lines, and designated them as TQ-series and TS-series clones, respectively. We then screened them by Western blotting to characterize their knockout status. Although the isolated clones showed various patterns of Jun and Fos family protein expression, TQ10, TQ15, and TQ22 clones did not express any Fos family proteins (Fig. 2A and B). In contrast, we were unable to isolate the JunFos-SKO clone (Figs. 2C-2E). Collectively, we obtained three Fos-QKO clones (14%) out of the 21 clones screened, but no JunFos-SKO clones from the 21 clones screened (Figs. 2B and 2E). We somehow managed to maintain the Fos-QKO clones for a few months, but found that they grew more slowly than vector-control cells, were prone to stochastic cell death, and were difficult to handle. These results suggest that the efficiency of simultaneous knockout is insufficient to recover complete seven-gene-KO clones or that the complete loss of all Jun/Fos family members is lethal or severely growth-impaired in THP-1 cells. The observation that c-Fos-ss-HKO polyclonal cells proliferated as well as the vector-control cells suggests that at least one member of the Fos family is essential for the normal survival or proliferation of THP-1 cells.Fig. 2Screening of Fos-QKO and JunFos-SKO clones using Protocol 3. Clones isolated from the Fos-QKO and JunFos-SKO cell lines were stimulated with 0.5 µM PMA for 120 min, and their whole-cell lysates were analyzed by Western blot. In all panels, β-actin blots were used as loading controls. (A) Clones of the TQ series (TQ1, TQ2, etc., and TQ23) isolated from the Fos-QKO polyclonal cells were screened for expression of Fos family proteins. (B) Expression profile of the Fos family proteins in TQ clones. Filled boxes indicate expression of the respective proteins. (C and D) Representative results of the Western blot screening for expression of Fos (C) and Jun (D) family proteins in TS clones isolated from the JunFos-SKO polyclonal cells. (E) Expression profile of the Fos and Jun family proteins in TS clones. Filled boxes indicate expression of the respective proteins. Screening of Fos-QKO and JunFos-SKO clones using Protocol 3. Clones isolated from the Fos-QKO and JunFos-SKO cell lines were stimulated with 0.5 µM PMA for 120 min, and their whole-cell lysates were analyzed by Western blot. In all panels, β-actin blots were used as loading controls. (A) Clones of the TQ series (TQ1, TQ2, etc., and TQ23) isolated from the Fos-QKO polyclonal cells were screened for expression of Fos family proteins. (B) Expression profile of the Fos family proteins in TQ clones. Filled boxes indicate expression of the respective proteins. (C and D) Representative results of the Western blot screening for expression of Fos (C) and Jun (D) family proteins in TS clones isolated from the JunFos-SKO polyclonal cells. (E) Expression profile of the Fos and Jun family proteins in TS clones. Filled boxes indicate expression of the respective proteins. In conclusion, we optimized the simultaneous multigene knockout protocol for THP-1 cells. THP-1 cells can differentiate into macrophage-like cells upon PMA treatment, acquiring the ability to produce cytokines. Therefore, multiplex gene KO in THP-1 cells would provide opportunities to investigate the molecular mechanisms underlying macrophage differentiation and cytokine production. Limitations •In this study, we roughly estimated knockout efficiencies by Western Blotting for the gene products of the targeted genes, but reduced protein expression does not necessarily reflect gene knockout. It could reflect transcriptional downregulation, translational inhibition, antibody epitope disruption without a frameshift, or even off-target effects. Therefore, DNA sequence analysis is required to confirm gene knockout unequivocally. The knockout efficiency of polyclonal cells can be estimated by deep sequencing analyses, such as amplicon sequencing of the sgRNA-target site [3]. For more precise determination of knockout status, isolate clones and perform PCR amplification and Sanger sequencing of the genomic DNA region containing the targeted sites.•In multigene knockout experiments, there is an inevitable trade-off between increasing the number of sgRNAs and the resulting nearly proportional increase in off-target mutations [2]. Therefore, we recommend generating at least two independent knockout cell lines with different target sites for each gene, and confirming that relevant phenotypes are identical between cell lines with the different targets.•Simultaneous induction of multiple DSBs on different chromosomes may cause a translocation, typically a reciprocal translocation [16]. Although translocations were likely rare in HeLa cells [3], they should be considered in multigene knockout experiments and verified after clone isolation, when needed.•We observed that the knockout clones thus obtained from HeLa or THP-1 cells are usually sensitive to puromycin, comparable to the parental cells, suggesting that the transfected DNA is rarely, if ever, integrated into the genome. Depending on the research purpose, however, integration of the introduced DNA into the genome may be problematic, and should therefore be checked after clone isolation, when needed.•As demonstrated by the Jun/Fos-KO experiments, the strategy of using polyclonal KO cell lines cannot be applied to genes important for cell survival or proliferation. For polyclonal knockout cells, we recommend avoiding long-term cultivation and confirming that expression of the targeted genes has not been recovered by the end of the experiments. •In this study, we roughly estimated knockout efficiencies by Western Blotting for the gene products of the targeted genes, but reduced protein expression does not necessarily reflect gene knockout. It could reflect transcriptional downregulation, translational inhibition, antibody epitope disruption without a frameshift, or even off-target effects. Therefore, DNA sequence analysis is required to confirm gene knockout unequivocally. The knockout efficiency of polyclonal cells can be estimated by deep sequencing analyses, such as amplicon sequencing of the sgRNA-target site [3]. For more precise determination of knockout status, isolate clones and perform PCR amplification and Sanger sequencing of the genomic DNA region containing the targeted sites.•In multigene knockout experiments, there is an inevitable trade-off between increasing the number of sgRNAs and the resulting nearly proportional increase in off-target mutations [2]. Therefore, we recommend generating at least two independent knockout cell lines with different target sites for each gene, and confirming that relevant phenotypes are identical between cell lines with the different targets.•Simultaneous induction of multiple DSBs on different chromosomes may cause a translocation, typically a reciprocal translocation [16]. Although translocations were likely rare in HeLa cells [3], they should be considered in multigene knockout experiments and verified after clone isolation, when needed.•We observed that the knockout clones thus obtained from HeLa or THP-1 cells are usually sensitive to puromycin, comparable to the parental cells, suggesting that the transfected DNA is rarely, if ever, integrated into the genome. Depending on the research purpose, however, integration of the introduced DNA into the genome may be problematic, and should therefore be checked after clone isolation, when needed.•As demonstrated by the Jun/Fos-KO experiments, the strategy of using polyclonal KO cell lines cannot be applied to genes important for cell survival or proliferation. For polyclonal knockout cells, we recommend avoiding long-term cultivation and confirming that expression of the targeted genes has not been recovered by the end of the experiments. •In this study, we roughly estimated knockout efficiencies by Western Blotting for the gene products of the targeted genes, but reduced protein expression does not necessarily reflect gene knockout. It could reflect transcriptional downregulation, translational inhibition, antibody epitope disruption without a frameshift, or even off-target effects. Therefore, DNA sequence analysis is required to confirm gene knockout unequivocally. The knockout efficiency of polyclonal cells can be estimated by deep sequencing analyses, such as amplicon sequencing of the sgRNA-target site [3]. For more precise determination of knockout status, isolate clones and perform PCR amplification and Sanger sequencing of the genomic DNA region containing the targeted sites.•In multigene knockout experiments, there is an inevitable trade-off between increasing the number of sgRNAs and the resulting nearly proportional increase in off-target mutations [2]. Therefore, we recommend generating at least two independent knockout cell lines with different target sites for each gene, and confirming that relevant phenotypes are identical between cell lines with the different targets.•Simultaneous induction of multiple DSBs on different chromosomes may cause a translocation, typically a reciprocal translocation [16]. Although translocations were likely rare in HeLa cells [3], they should be considered in multigene knockout experiments and verified after clone isolation, when needed.•We observed that the knockout clones thus obtained from HeLa or THP-1 cells are usually sensitive to puromycin, comparable to the parental cells, suggesting that the transfected DNA is rarely, if ever, integrated into the genome. Depending on the research purpose, however, integration of the introduced DNA into the genome may be problematic, and should therefore be checked after clone isolation, when needed.•As demonstrated by the Jun/Fos-KO experiments, the strategy of using polyclonal KO cell lines cannot be applied to genes important for cell survival or proliferation. For polyclonal knockout cells, we recommend avoiding long-term cultivation and confirming that expression of the targeted genes has not been recovered by the end of the experiments. •In this study, we roughly estimated knockout efficiencies by Western Blotting for the gene products of the targeted genes, but reduced protein expression does not necessarily reflect gene knockout. It could reflect transcriptional downregulation, translational inhibition, antibody epitope disruption without a frameshift, or even off-target effects. Therefore, DNA sequence analysis is required to confirm gene knockout unequivocally. The knockout efficiency of polyclonal cells can be estimated by deep sequencing analyses, such as amplicon sequencing of the sgRNA-target site [3]. For more precise determination of knockout status, isolate clones and perform PCR amplification and Sanger sequencing of the genomic DNA region containing the targeted sites. In this study, we roughly estimated knockout efficiencies by Western Blotting for the gene products of the targeted genes, but reduced protein expression does not necessarily reflect gene knockout. It could reflect transcriptional downregulation, translational inhibition, antibody epitope disruption without a frameshift, or even off-target effects. Therefore, DNA sequence analysis is required to confirm gene knockout unequivocally. The knockout efficiency of polyclonal cells can be estimated by deep sequencing analyses, such as amplicon sequencing of the sgRNA-target site [3]. For more precise determination of knockout status, isolate clones and perform PCR amplification and Sanger sequencing of the genomic DNA region containing the targeted sites. •In multigene knockout experiments, there is an inevitable trade-off between increasing the number of sgRNAs and the resulting nearly proportional increase in off-target mutations [2]. Therefore, we recommend generating at least two independent knockout cell lines with different target sites for each gene, and confirming that relevant phenotypes are identical between cell lines with the different targets. In multigene knockout experiments, there is an inevitable trade-off between increasing the number of sgRNAs and the resulting nearly proportional increase in off-target mutations [2]. Therefore, we recommend generating at least two independent knockout cell lines with different target sites for each gene, and confirming that relevant phenotypes are identical between cell lines with the different targets. •Simultaneous induction of multiple DSBs on different chromosomes may cause a translocation, typically a reciprocal translocation [16]. Although translocations were likely rare in HeLa cells [3], they should be considered in multigene knockout experiments and verified after clone isolation, when needed. Simultaneous induction of multiple DSBs on different chromosomes may cause a translocation, typically a reciprocal translocation [16]. Although translocations were likely rare in HeLa cells [3], they should be considered in multigene knockout experiments and verified after clone isolation, when needed. •We observed that the knockout clones thus obtained from HeLa or THP-1 cells are usually sensitive to puromycin, comparable to the parental cells, suggesting that the transfected DNA is rarely, if ever, integrated into the genome. Depending on the research purpose, however, integration of the introduced DNA into the genome may be problematic, and should therefore be checked after clone isolation, when needed. We observed that the knockout clones thus obtained from HeLa or THP-1 cells are usually sensitive to puromycin, comparable to the parental cells, suggesting that the transfected DNA is rarely, if ever, integrated into the genome. Depending on the research purpose, however, integration of the introduced DNA into the genome may be problematic, and should therefore be checked after clone isolation, when needed. •As demonstrated by the Jun/Fos-KO experiments, the strategy of using polyclonal KO cell lines cannot be applied to genes important for cell survival or proliferation. For polyclonal knockout cells, we recommend avoiding long-term cultivation and confirming that expression of the targeted genes has not been recovered by the end of the experiments. As demonstrated by the Jun/Fos-KO experiments, the strategy of using polyclonal KO cell lines cannot be applied to genes important for cell survival or proliferation. For polyclonal knockout cells, we recommend avoiding long-term cultivation and confirming that expression of the targeted genes has not been recovered by the end of the experiments. Ethics statements This work did not involve human subjects, animal experiments, or data collected from social media platforms. Declaration of AI use During the preparation of this work, the authors used ChatGPT and Google Gemini in order to search for and collect relevant literature and included only references whose credibility had been verified through PubMed searches and subsequent identification of the individual papers. Supplementary material and/or additional information [OPTIONAL] No supplementary materials or additional information CRediT authorship contribution statement Chihiro Ito: Conceptualization, Methodology, Investigation, Visualization, Data curation, Writing – original draft, Supervision. Yuki Kinomura: Investigation, Visualization. Kensho Kawagoe: Investigation, Visualization. Shinobu Fujii: Conceptualization, Supervision. Toshihiro Fujii: Conceptualization, Methodology, Supervision. Rikiro Fukunaga: Conceptualization, Methodology, Investigation, Visualization, Data curation, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.